Date: 2018-05-25
Type of information: Nomination
Compound: chairman of the board
Company: Imcheck Therapeutics (France)
Therapeutic area: Cancer - Oncology - Autoimmune diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 25, 2018, ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announced the appointment of Dr. Debasish Roychowdhury as its independent Chairman of the Board.
- Dr. Roychowdhury is a hematologist/oncologist with over a decade of patient care, academic research and teaching experience as well as over 15 years of pharmaceutical industry and senior management experience. During his career in the top 10 pharmaceutical companies, Dr. Roychowdhury was the Senior Vice President and Head of the Global Oncology Division at Sanofi. Prior to that, he served as the Vice President for Clinical Development at GSK and directed the Oncology global regulatory group at Eli Lilly.
- Among many other achievements, Debasish career includes 9 drug approvals in the U.S. and in Europe, the establishment of Sanofi’s Oncology Division (notably Genzyme’s integration), founding Partner Therapeutics and successfully supporting biotech companies (notably Seragon Pharmaceuticals sale to Roche/Genentech).
- Debasish currently consults many pharma & biotech companies and serves as a member of the Board of Directors for Partner Therapeutics, Lytix Biopharma AS, Celyad S.A., and Fund+, a life sciences investment fund.
Financial terms:
Latest news:
Is general: Yes
